ImageneBio (IMA) Fundamentals 2026 — Revenue Analysis | SniperIQ
ImageneBio (IMA) is a US-listed Healthcare company in Biotechnology with a market capitalization of $66M, trading at $5.88 on the NASDAQ. This SniperIQ fundamentals page covers ImageneBio's valuation, profitability (net margin 0.0%), revenue ($800,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ImageneBio's market cap?
ImageneBio (IMA) has a market capitalization of approximately $66M, trading at $5.88 on the NASDAQ. Market cap moves with the live share price.
What is ImageneBio's P/E ratio?
ImageneBio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ImageneBio?
ImageneBio runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ImageneBio generate?
ImageneBio reported revenue of $800,000 for fiscal year 2025, with net income of -$45M and earnings per share (EPS) of -10.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ImageneBio pay a dividend?
ImageneBio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ImageneBio financially healthy?
ImageneBio carries a debt-to-equity ratio of 0.07x and a current ratio of 18.39x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ImageneBio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ImageneBio (IMA) the key facts are: market cap $66M, revenue $800,000, 52-week range 3.94-18. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ImageneBio's full fundamentals live
Get ImageneBio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.